Literature DB >> 24995973

YAP1 takes over when oncogenic K-Ras slumbers.

Florian R Greten1.   

Abstract

It is of great therapeutic importance to understand why tumors relapse after the failure of therapies targeting oncogenes to which cancer cells are addicted. In this issue, Kapoor et al. and Shao et al. identify the transcriptional coactivator YAP1 as a central driver of compensation for the loss of K-Ras signaling in K-Ras-dependent cancers.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24995973     DOI： 10.1016/j.cell.2014.06.021

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  13 in total

1.  A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.

Authors:  Shumei Song; Min Xie; Ailing W Scott; Jiankang Jin; Lang Ma; Xiaochuan Dong; Heath D Skinner; Randy L Johnson; Sheng Ding; Jaffer A Ajani
Journal:  Mol Cancer Ther       Date:  2017-11-22       Impact factor: 6.261

2.  eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.

Authors:  Jan Strnadel; Sunkyu Choi; Ken Fujimura; Huawei Wang; Wei Zhang; Meghan Wyse; Tracy Wright; Emilie Gross; Carlos Peinado; Hyun Woo Park; Jack Bui; Jonathan Kelber; Michael Bouvet; Kun-Liang Guan; Richard L Klemke
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

Review 3.  Cell density regulates cancer metastasis via the Hippo pathway.

Authors:  Ghada M Sharif; Anton Wellstein
Journal:  Future Oncol       Date:  2015-11-12       Impact factor: 3.404

4.  Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling.

Authors:  G M Sharif; M O Schmidt; C Yi; Z Hu; B R Haddad; E Glasgow; A T Riegel; A Wellstein
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

5.  Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.

Authors:  Matthew L Fisher; Daniel Grun; Gautam Adhikary; Wen Xu; Richard L Eckert
Journal:  Oncotarget       Date:  2017-11-22

6.  Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.

Authors:  Ping-Chih Hsu; Jinbai Miao; Zhen Huang; Yi-Lin Yang; Zhidong Xu; Joanna You; Yuyuan Dai; Che-Chung Yeh; Geraldine Chan; Shu Liu; Anatoly Urisman; Cheng-Ta Yang; David M Jablons; Liang You
Journal:  J Cell Mol Med       Date:  2018-03-24       Impact factor: 5.310

7.  Overexpression of E2F mRNAs associated with gastric cancer progression identified by the transcription factor and miRNA co-regulatory network analysis.

Authors:  XiaoTian Zhang; ZhaoHui Ni; ZiPeng Duan; ZhuoYuan Xin; HuaiDong Wang; JiaYi Tan; GuoQing Wang; Fan Li
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

8.  Role of Yes-associated protein in cancer: An update.

Authors:  Ramazan Abylkassov; Yingqiu Xie
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

9.  Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1.

Authors:  Andrew Fesler; Hua Liu; Jingfang Ju
Journal:  Oncotarget       Date:  2017-12-19

10.  The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer.

Authors:  De-Wei Wu; Po-Lin Lin; Lee Wang; Chi-Chou Huang; Huei Lee
Journal:  Theranostics       Date:  2017-02-27       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.